Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, after the company halted two high-dose arms in its Phase 2 TROPOS trial of ...

While not a mind-blowing move, it is good to see that the Keros Therapeutics, Inc. (NASDAQ:KROS) share price has gained 12% in the last three months. But that isn't much consolation for the painful ...

Dec 12 (Reuters) - Keros Therapeutics (KROS.O), opens new tab said on Thursday it had paused giving patients higher doses of its high blood pressure treatment in a mid-stage study after reports of a ...

Keros Therapeutics (NASDAQ:KROS) stock plunged 73% Thursday after the company said it has halted two arms of a Phase 2 clinical study of its drug cibotercept in patients with pulmonary arterial ...

Shares of Keros Therapeutics, Inc. (KROS) traded 14% higher on Thursday morning after the company adopted a poison pill plan to fend off hostile takeovers by a number of investors that have rapidly ...

Keros Therapeutics, Inc. trades near cash value after abandoning cibotercept, focusing solely on early-stage KER-065 for Duchenne muscular dystrophy, or DMD. KROS holds $690 million in cash and plans ...

Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy AUSTIN, Texas, June 9, 2025 /PRNewswire/ -- ADAR1 ...